Key Developments: Ventripoint Diagnostics Ltd (VPT.V)

VPT.V on TSX Venture Exchange

0.06CAD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$0.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
157,377
52-wk High
$0.17
52-wk Low
$0.03

Search Stocks

Latest Key Developments (Source: Significant Developments)

Ventripoint Diagnostics Ltd signs distributor agreement with Shandong Realcan Pharmaceuticals Co. Ltd. and intends to complete strategic investment
Tuesday, 2 Sep 2014 07:50am EDT 

Ventripoint Diagnostics Ltd:Signs distribution agreement with Shandong Realcan Pharmaceuticals Co. Ltd and will make application to the TSX Venture Exchange to allow strategic investment in Ventripoint of up to C$4,000,000.Says its intention to complete a non-brokered private placement offering of up to C$4,000,000 of units of the Corporation (each, a "Unit") at a Unit price of C$0.06.Says each unit will consist of one common share and one half of one common share purchase warrant.Says each whole warrant will entitle the holder thereof to acquire one additional common share at a price of C$0.12 per share for a period of 2 years after the closing.Realcan will subscribe for about C$2,000,000 of the Offering and will introduce the company to other strategic investors.  Full Article

Ventripoint Diagnostics Ltd announces closing of first tranche of private placement and shares for debt
Monday, 23 Jun 2014 07:00am EDT 

Ventripoint Diagnostics Ltd:Completes first tranche of private placement of 24,951,426 units for gross proceeds of $1,996,114.Each unit is comprised of one common share and one half of one common share purchase warrant.Each full Warrant is exercisable into one additional Common Share at an exercise price of $0.12 until June 20, 2016.Private Placement was about 33 pct non-brokered and 67 pct brokered, with D&D Securities Inc. acting as agent of corporation in brokered portion of private placement.Corporation will use proceeds for sales and marketing and general working capital purposes.Three of subscribers in the private placement accepted units as payment in full of outstanding secured debentures previously issued by the corporation as a shares-for-debt transaction.As a result of shares for debt, the corporation's net debt has been reduced by $773,626.  Full Article

Ventripoint Diagnostics Ltd Announces Clarification Of Terms And Closing Of Further $500,000 Debenture Unit Private Placement
Tuesday, 3 Sep 2013 04:11pm EDT 

Ventripoint Diagnostics Ltd announced that it has completed its non-brokered private placement of debenture units with minor modifications as announced on August 28, 2013. The Corporation issued $500,000 in $1,000 principal amounts of convertible non-secured debentures (Debentures), which shall mature two years from the date of issuance of the Debentures (the Maturity Date) and issued a total of 2,500,000 common share purchase warrants with an exercise price of $0.15 for a period of two years, provided that if the daily volume weighted average price on the TSX Venture Exchange (the Exchange) for the common shares exceeds $0.20 for 20 consecutive trading days at any time during the term then the warrants will expire within 30 days following such period. The Corporation intends to use the proceeds from the Offering to incur expenditures for: (i) product and service commercialization of the VMS; (ii) clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and (iii) for general working capital purposes and potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd Announces Further $500,000 Unit Debenture Private Placement
Wednesday, 28 Aug 2013 04:05pm EDT 

Ventripoint Diagnostics Ltd announced that it intends to complete a second non-brokered private placement of up to CAD500,000 (the Offering) of debenture units of the Corporation at a price of $1,000 per unit (Units). The Units will be comprised of $1,000 principal amount of convertible non-secured debentures (Debentures), which shall mature three years from the date of issuance of the Debentures (the Maturity Date) and 5,000 common share purchase warrants with an exercise price of $0.15 for a period of three years with an acceleration clause that if the daily volume weighted average price on the TSX Venture Exchange (the Exchange) for the common shares exceeds $0.20 for 20 consecutive trading days at any time during the term then the warrants will expire within 30 days following such period. Depending on market conditions, the Corporation reserves the right to increase the maximum gross proceeds under the Offering, subject to approval of the Exchange.  Full Article

Ventripoint Diagnostics Ltd Announces Closing of Debenture Unit Private Placement
Thursday, 22 Aug 2013 04:05pm EDT 

Ventripoint Diagnostics Ltd announced that it has completed its non-brokered private placement of debenture units of the Corporation previously announced on August 1, 2013 (the Offering). The Company issued $300,000 in $1,000 principal amount of convertible non-secured debentures (Debentures), which shall mature three years from the date of issuance of the Debentures (the Maturity Date) and issued a total of 1,500,000 common share purchase warrants with an exercise price of $0.15 for a period of three years. The Corporation intends to use the proceeds from the Offering to incur expenditures for: product and service commercialization of the VMS; clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and for general working capital purposes and potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd Announces $500,000 Debenture Unit Private Placement
Thursday, 1 Aug 2013 10:46am EDT 

Ventripoint Diagnostics Ltd announcesd that it intends to complete a non-brokered private placement of up to CDN$500,000 of debenture units of the Corporation at a price of $1,000 per unit. The Units will be comprised of $1,000 principal amount of convertible non-secured debentures, which shall mature three years from the date of issuance of the Debentures and 5,000 common share purchase warrants with an exercise price of $0.15 for a period of three years. Depending on market conditions, the Corporation reserves the right to increase the maximum gross proceeds under the Offering, subject to approval of the TSX Venture Exchange. The Debentures shall bear a 12% annual simple interest calculated on the principal amount, with any accrued but unpaid interest under the Debentures due and payable on the anniversary of the Debenture in either cash or Common Shares with the number of Common Shares being determined by using the 10 day volume-weighted average price of the Common Shares on the Exchange on that date that is five days prior to the anniversary date. The Corporation intends to use the proceeds from the Offering to incur expenditures for: (i) product and service commercialization of the VMS; (ii) clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and (iii) for general working capital purposes and potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd Announces Closing Of Private Placement
Monday, 29 Jul 2013 07:09pm EDT 

Ventripoint Diagnostics Ltd announced that it has completed the second closing of the second of two previously announced non-brokered private placements. The Company has issued an aggregate of 50 units for gross proceeds of USD50,000 (the Unit Private Placement). Each Unit consists of USD1,100 principal amount of non-convertible secured debentures (Unit Debentures), which shall mature three years from the date of issuance and 2,000 common shares in the capital of the Company (the Common Shares). Each Unit Debenture is subject to a 10% capital discount to the subscriber such that for every USD1.00 Unit Debenture acquired, the Company shall owe, on the maturity date, an amount equal to USD1.10 to the subscriber minus any payments of principal to date. Any interest due under the terms of the Unit Debentures shall only be paid and calculated against the principal amount actually provided to the Company (i.e. USD1.00) by the subscriber and not calculated against the inflated principal paid on the maturity date (i.e. USD1.10). The Company intends to use the proceeds from the Unit Private Placement for product and service commercialization of the VMS machines; clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and for general working capital purposes and to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd Announces Closing Of Private Placement And Proposed Issuance Of Shares For Debt
Thursday, 23 May 2013 06:04pm EDT 

Ventripoint Diagnostics Ltd announced that it has completed the first of its two previously announced non-brokered private placements. The Company has issued an aggregate of USD748,000 principal amount of non-convertible secured debentures (the Non-Unit Debentures) which mature on July 18, 2014 pursuant to the non-brokered private placement (the Debenture Private Placement) of non-convertible secured debentures (the Debentures). The Debentures will bear interest at a rate of 12% per annum. Any accrued but unpaid interest under the Debentures shall be due and payable on December 1st of each calendar year. The December 1, 2013 interest may, subject to the approval of the TSX Venture Exchange (Exchange), be paid in Common Shares, with the number of Common Shares being determined by using the preceding 10 day volume-weighted average price of the Common Shares on the Exchange, subject to Exchange approval. All subsequent interest payments shall be made in cash and the final payment of accrued interest shall be payable upon maturity of the Debentures The Company intends to use the proceeds from the Debenture Private Placement for: (i) product and service commercialization of the VMS machines; (ii) clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and (iii) for general working capital purposes and potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd Announces Private Placements
Monday, 6 May 2013 04:30pm EDT 

Ventripoint Diagnostics Ltd announced that it intends to complete a non-brokered private placement of up to 1,000 units of the Company at a price of $1,000 per Unit for gross proceeds of up to $1,000,000. Each Unit will consist of $1,100 principal amount of non-convertible secured debentures, which shall mature three years from the date of issuance and 2,000 common shares in the capital of the Company. The Corporation also announced a non-brokered private placement of up to $800,000 of non-convertible secured debentures in a principal amount of $1,000 per Non-Unit Debenture which shall mature on July 18, 2014. The Unit Private Placement and the Non-Unit Private Placement are collectively referred to herein as the Private Placements. The Unit Debentures and Non-Unit Debentures are collectively referred to herein as the Debentures. The Company intends to use the proceeds from the Private Placements for: (i) product and service commercialization of the VMS machines; (ii) clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and (iii) for general working capital purposes and potentially to repay debt and outstanding payables. The Private Placements are subject to the approval of the TSX Venture Exchange. The securities will be subject to a four-month hold period, in accordance with applicable securities laws.  Full Article

Ventripoint Diagnostics Ltd Announces Closing Of Offering
Monday, 22 Apr 2013 07:45am EDT 

Ventripoint Diagnostics Ltd announced that, further to its press release dated April 1, 2013, it has completed the final closing of its previously announced private placement of units (the Unit) of the Company (the Offering). In connection with the final closing of the Offering, the Company issued 3,487,000 Units at a price of $0.10 per Unit for gross proceeds of $348,700. As a result of the two closings, the Company has raised total gross proceeds of $933,700 pursuant to the Offering. Each Unit is comprised of one common share (Common Share) of the Company and one-half of one Common Share purchase warrant (Warrant), with each Warrant entitling the holder thereof to purchase one Common Share at a price of $0.15 per share for a period of two years from the date of issuance. The proceeds made available through the sale of Units will be used for the general working capital needs of the Company.  Full Article

No consensus analysis data available.
Search Stocks